Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity
Interacts with HTR6 (PubMed:23027611). Interacts with SPRED2 (PubMed:34626534)
Detected in brain, peripheral nerve, lung, colon and muscle
Binds phospholipids via its C-terminal CRAL-TRIO domain. Binds primarily glycerophospholipids with monounsaturated C18:1 and/or C16:1 fatty acid moieties and a phosphatidylethanolamine or phosphatidylcholine headgroup. Has lesser affinity for lipids containing phosphatidylserine and phosphatidylinositol
A disease characterized by patches of skin pigmentation (cafe-au-lait spots), Lisch nodules of the iris, tumors in the peripheral nervous system and fibromatous skin tumors. Individuals with the disorder have increased susceptibility to the development of benign and malignant tumors.
An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.
A syndrome characterized by the presence of pulmonary stenosis, cafe-au-lait spots, and intellectual disability. It is considered as an atypical form of neurofibromatosis.
Considered to be an alternative form of neurofibromatosis, showing multiple spinal tumors.
Characterized by manifestations of both NF1 and Noonan syndrome (NS). NS is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis.
A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to ZNF100, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 266
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02811718 | Neurofibromatosis 2 | Resiliency Training for Patients With NF2 Via Videoconferencing With Skype | NA | COMPLETED |
| NCT04534283 | Cancer, Cancer Metastatic, BRAF V600E, MEK1 Gene Mutation, MEK2 Gene Mutation, ERK Mutation, RAF1 Gene Mutation | A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | PHASE2 | TERMINATED |
| NCT04800822 | Solid Tumor | PF-07284892 in Participants With Advanced Solid Tumors | PHASE1 | TERMINATED |
| NCT00111384 | Neurofibromatosis Type 1, Legius Syndrome | Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) | N/A | COMPLETED |
| NCT05521048 | Neurofibromatosis Type 2 | Doxycycline in Cutaneous Schwannoma (NF2) | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT00911248 | Neurofibromatosis 2 | PTC299 for Treatment of Neurofibromatosis Type 2 | PHASE2 | TERMINATED |
| NCT01338857 | neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma | Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas | PHASE2 | TERMINATED |
| NCT05831995 | Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation | Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. | PHASE1 | TERMINATED |
| NCT05331105 | Neurofibromatosis 1, Plexiform Neurofibromas | HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | PHASE2 | RECRUITING |
| NCT06188741 | Neurofibromatosis 1, Plexiform Neurofibroma | Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | PHASE2 | RECRUITING |